Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistant estrogen receptor-positive breast cancer.

Breast Cancer

Lisa A. Carey, MD

Oct

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Lisa A. Carey, MD, on the TNT Trial

Hope S. Rugo, MD, on the Phase II FIRST Study

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease

Preclinical Study Examines Relationship Between Aging Breast Tissue and Invasive Breast Cancer

Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment in Metastatic Colorectal Cancer 60-Day Mortality

First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer

Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis